Results from the Phase II STRIVE trial demonstrates favorable safety, tolerability and efficacy of the antifungal drug, rezafungin.
Browsing: Disease Area > Fungal
The Microbe Directory is a collective research effort aiming to profile over 7,000 microbes in order to provide further information for any researchers carrying out metagenomic analyses. We spoke to two of the Project Leaders, Heba Shaaban and David Westfall about the project, how it’s being used in research and how you can get involved.
Infectious diseases remain a major cause of mortality across the globe, so if pathogens could therefore be harnessed as a weapon, the implications would certainly be severe and far-reaching. Find out more about biothreats and bioterrorism in our explainer.
To round up 2017, we asked our Expert panel to choose their top papers from the year. Here, you can discover these articles and the reasons why they were chosen.
Want to find out what’s been happening this year? Editor, Martha Powell, highlights the best of 2017’s infectious diseases research in an A–Z.
This study looks at Candida tropicalis, evaluating if radiation used in radiotherapy can cause changes in the virulence potential.
A new study has identified cyclin-dependent kinases as the key regulator of chromatin snares that are essential for neutrophil immune defense.
New drugs with antifungal action need to be developed. Here, the authors investigate the antifungal activity of MOL3, a small molecule that was selected by virtual screening, against Candida spp.
A novel CRISPR–Cas9-based gene drive platform has been developed by researchers and may help us understand some of the genetic networks underlying virulence in fungal pathogen, Candida albicans.
This research article from Future Microbiology investigates the species distribution and antifungal susceptibility profiles of yeast isolates causing invasive infections across Beijing.